Education
About Us
Working with TipRanks
Follow Us
Elite Pharmaceuticals (ELTP)
OTHER OTC:ELTP
Total Valuation
Elite Pharmaceuticals has a market cap or net worth of $741.00M. The enterprise value is $464.34M.
Market Cap$741.00M
Enterprise Value$464.34M
Share Statistics
Elite Pharmaceuticals has 1,070,963,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,070,963,100
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Elite Pharmaceuticals’s return on equity (ROE) is -0.08 and return on invested capital (ROIC) is 1809.64%.
Return on Equity (ROE)-0.08
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)1809.64%
Return on Capital Employed (ROCE)0.23
Revenue Per Employee1.31M
Profits Per Employee-67.42K
Employee Count64
Asset Turnover0.87
Inventory Turnover2.71
Valuation Ratios
The current PE Ratio of Elite Pharmaceuticals is ―. Elite Pharmaceuticals’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value8.68
Price to FCF―
Price to Operating Cash Flow82.38
PEG Ratio―
Income Statement
In the last 12 months, Elite Pharmaceuticals had revenue of 84.04M and earned -4.31M in profits. Earnings per share was 0.00.
Revenue84.04M
Gross Profit40.09M
Operating Income19.60M
Pretax Income-52.14K
Net Income-4.31M
EBITDA2.84M
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was 19.09M and capital expenditures -1.06M, giving a free cash flow of 18.02M billion.
Operating Cash Flow19.09M
Free Cash Flow18.02M
Free Cash Flow per Share0.02
Dividends & Yields
Elite Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.37
52-Week Price Change74.36%
50-Day Moving Average0.60
200-Day Moving Average0.54
Relative Strength Index (RSI)58.60
Average Volume (3m)1.76M
Important Dates
Elite Pharmaceuticals upcoming earnings date is Nov 18, 2025, TBA (Confirmed).
Last Earnings DateAug 14, 2025
Next Earnings DateNov 18, 2025
Ex-Dividend Date―
Financial Position
Elite Pharmaceuticals as a current ratio of 4.88, with Debt / Equity ratio of 20.40%
Current Ratio4.88
Quick Ratio3.50
Debt to Market Cap0.02
Net Debt to EBITDA-0.14
Interest Coverage Ratio25.38
Taxes
In the past 12 months, Elite Pharmaceuticals has paid 4.26M in taxes.
Income Tax4.26M
Effective Tax Rate-81.75
Enterprise Valuation
Elite Pharmaceuticals EV to EBITDA ratio is 163.34, with an EV/FCF ratio of 94.17.
EV to Sales5.52
EV to EBITDA163.34
EV to Free Cash Flow94.17
EV to Operating Cash Flow62.28
Balance Sheet
Elite Pharmaceuticals has $21.74M in cash and marketable securities with $6.68M in debt, giving a net cash position of $15.06M billion.
Cash & Marketable Securities$21.74M
Total Debt$6.68M
Net Cash$15.06M
Net Cash Per Share$0.01
Tangible Book Value Per Share$0.04
Margins
Gross margin is 47.70%, with operating margin of 23.32%, and net profit margin of -5.13%.
Gross Margin47.70%
Operating Margin23.32%
Pretax Margin-0.06%
Net Profit Margin-5.13%
EBITDA Margin3.38%
EBIT Margin0.86%
Analyst Forecast
The average price target for Elite Pharmaceuticals is $0.50, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$0.50
Price Target Upside-26.47% Downside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast58.70%
EPS Growth Forecast-152.33%